VIDEO: Avoid IOP ‘peaks and troughs’ by using stand-alone canal-based MIGS

ByManjool Shah, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

NEW YORK — In this presentation from OSN New York, Manjool M. Shah, MD, discusses why stand-alone canal-based MIGS is an alternative to topical medications for glaucoma treatment.

According to Shah, even when patients adhere to topical therapy, there are still “peaks and troughs” of efficacy. Tools such as the iStent infinite (Glaukos) are FDA-approved options to improve IOP in a “small package.”

When deciding whether MIGS is the right fit for a patient, “we like to bring it back home to not only intraocular pressure but quality of life and the challenges with the other ways of doing things,” he said.

Published by:

Sources/Disclosures

Collapse

Source:

Shah M. Why I’m bullish on stand-alone canal-based MIGS. Presented at: OSN New York and OSN New York Retina; Nov. 8-10, 2024; New York.

Disclosures: Shah reports having financial disclosures for AbbVie, Alcon, Bausch + Lomb, Elios, Glaukos, Nova Eye Medical and ONL Therapeutics.

OSN New York and OSN New York Retina

Read more

VIDEO: Avoid IOP ‘peaks and troughs’ by using stand-alone canal-based MIGS

Related Content